NASD · Healthcare · Diagnostics & Research · USA
Personalis Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.
Personalis develops and markets advanced cancer genomic testing services for physicians, pharmaceutical companies, and diagnostics firms. The company offers tumor-informed liquid biopsy tests to detect minimal residual disease and monitor therapy response, comprehensive tumor profiling for treatment selection, and sequencing services for research and diagnostic use.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Personalis Inc stock.
Overvalued: intrinsic value $1.83 per share, market price $15.88, margin of safety -769.9% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $1.83; the price of $15.88 is 770% above that value.
Leak Score: 27/100 on 9 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
21 more in this industry show a wider margin of safety.
PSNL is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $1.83; the price of $15.88 is 770% above that value.
$1.83 per share (as of the 2026-10-19 close), against a market price of $15.88. That is a margin of safety of -769.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
27 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.